<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1213824</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2023.1213824</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Nano-sized warriors: zinc chromium vanadate nanoparticles as a dual solution for eradicating waterborne enterobacteriaceae and fighting cancer</article-title>
<alt-title alt-title-type="left-running-head">Rehman et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2023.1213824">10.3389/fphar.2023.1213824</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Rehman</surname>
<given-names>Suriya</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1220744/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alahmari</surname>
<given-names>Fatimah</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2297785/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aldossary</surname>
<given-names>Laila</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alhout</surname>
<given-names>Maryam</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aljameel</surname>
<given-names>Suhailah S.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ali</surname>
<given-names>Syed Mehmood</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2335509/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Sabir</surname>
<given-names>Jamal S. M.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/256341/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khan</surname>
<given-names>Firdos Alam</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/631518/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Rather</surname>
<given-names>Irfan A.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/275158/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Epidemic Diseases Research</institution>, <institution>Institute for Research and Medical Consultations (IRMC)</institution>, <institution>Imam Abdulrahman Bin Faisal University</institution>, <addr-line>Dammam</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Nanomedicine Research</institution>, <institution>Institute for Research and Medical Consultations (IRMC)</institution>, <institution>Imam Abdulrahman Bin Faisal University</institution>, <addr-line>Dammam</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Summer Research Program</institution>, <institution>Institute for Research and Medical Consultations (IRMC)</institution>, <institution>Department of Environmental Sciences</institution>, <institution>College of Science</institution>, <institution>Imam Abdulrahman Bin Faisal University</institution>, <addr-line>Dammam</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Chemistry</institution>, <institution>College of Science</institution>, <institution>Imam Abdulrahman Bin Faisal University</institution>, <addr-line>Dammam</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Biomedical Engineering</institution>, <institution>College of Engineering</institution>, <institution>Imam Abdulrahman Bin Faisal University</institution>, <addr-line>Dammam</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Department of Biological Science</institution>, <institution>Faulty of Science</institution>, <institution>King Abdulaziz University</institution>, <addr-line>Jeddah</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Center of Excellence in Bionanoscience Research</institution>, <institution>King Abdulaziz University</institution>, <addr-line>Jeddah</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff8">
<sup>8</sup>
<institution>Department of Stem Cell Research</institution>, <institution>Institute for Research and Medical Consultations (IRMC)</institution>, <institution>Imam Abdulrahman Bin Faisal University</institution>, <addr-line>Dammam</addr-line>, <country>Saudi Arabia</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1181458/overview">Nasir Siddiqui</ext-link>, King Saud University, Saudi Arabia</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1108088/overview">Hamed Barabadi</ext-link>, Shahid Beheshti University of Medical Sciences, Iran</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1800301/overview">Hosam Gharib Abdelhady</ext-link>, Sam Houston State University, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1604095/overview">Muzaffar Iqbal</ext-link>, King Saud University, Saudi Arabia</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Suriya Rehman, <email>surrehman@iau.edu.sa</email>; Jamal S. M. Sabir, <email>jsabir@kau.edu.sa</email>; Irfan A. Rather, <email>ammm@kau.edu.sa</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>07</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1213824</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>04</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Rehman, Alahmari, Aldossary, Alhout, Aljameel, Ali, Sabir, Khan and Rather.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Rehman, Alahmari, Aldossary, Alhout, Aljameel, Ali, Sabir, Khan and Rather</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The revolution of biomedical applications has opened new avenues for nanotechnology. Zinc Chromium vanadate nanoparticles (VCrZnO4 NPs) have emerged as an up-and-coming candidate, with their exceptional physical and chemical properties setting them apart. In this study, a one-pot solvothermal method was employed to synthesize VCrZnO4 NPs, followed by a comprehensive structural and morphological analysis using a variety of techniques, including X-Ray diffraction, scanning electron microscopy, high-resolution transmission electron microscopy, Energy-dispersive X-ray, and X-ray photoelectron spectroscopy. These techniques confirmed the crystallinity of the NPs. The VCrZnO4 NPs were tested for their antibacterial activity against primary contaminants such as Enterobacteriaceae, including <italic>Shigella flexneri</italic>, <italic>Salmonella cholerasis</italic>, and <italic>Escherichia coli</italic>, commonly found in hospital settings, using the broth dilution technique. The results indicated a stronger antibacterial activity of VCrZnO4 NPs against <italic>Shigella</italic> and <italic>Salmonella</italic> than <italic>E. coli.</italic> Electron microscopy showed that the NPs caused severe damage to the bacterial cell wall and membrane, leading to cell death. In addition, the study evaluated the anticancer activities of the metal complexes <italic>in vitro</italic> using colorectal cancer cells (HCT-116) and cervical cancer cells (HELA), along with non-cancer cells and human embryonic kidney cells (HEK-293). A vanadium complex demonstrated efficient anticancer effects with half-inhibitory concentrations (IC<sub>50</sub>) of 38.50&#x2b;3.50&#xa0;g/mL for HCT-116 cells and 42.25&#x2b;4.15&#xa0;g/mL for HELA cells. This study highlights the potential of Zinc Chromium vanadate nanoparticles as promising candidates for antibacterial and anticancer applications. Various advanced characterization techniques were used to analyze the properties of nanomaterials, which may help develop more effective and safer antibacterial and anticancer agents in the future.</p>
</abstract>
<kwd-group>
<kwd>nanomaterial</kwd>
<kwd>nanotherapeutics</kwd>
<kwd>antibacterial activity</kwd>
<kwd>anticancer: small molecule</kwd>
<kwd>zinc chromium vanadate</kwd>
</kwd-group>
<contract-num rid="cn001">IFPIP-57-130-1443</contract-num>
<contract-sponsor id="cn001">King Abdulaziz University<named-content content-type="fundref-id">10.13039/501100004054</named-content>
</contract-sponsor>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Experimental Pharmacology and Drug Discovery</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>In recent years, the use of metal ions in combination with organic or inorganic ligands to form complexes has gained significant attention due to their enhanced activity and potential biomedical applications. This gave the metal ion complexes far greater utility in medicine, chemical, pharmaceuticals, and agricultural industries (<xref ref-type="bibr" rid="B22">Kongot et al., 2020</xref>). Many studies indicated the detailed analysis and focused on the chemistry and synthesis of such metal compounds for their potential applications in the clinical treatment of various diseases, including communicable (infectious diseases) and non-communicable (cancer) diseases. As a result, recent research has shifted toward synthesizing metal complexes with potential biological properties, such as an antimicrobial and anticancer action. Recent studies have indicated that complexes of metals such as chromium, cobalt, copper, vanadium, manganese, and zinc have huge potential as antimicrobial, anticancer, antioxidant, and antidiabetic properties (<xref ref-type="bibr" rid="B43">Senthil Raja et al., 2012</xref>; <xref ref-type="bibr" rid="B2">Al-Hazmi et al., 2020</xref>). In this regard, Vanadium and chromium play crucial roles and are known for their significant bioactivities like antimicrobial, anticancer, and antiviral (<xref ref-type="bibr" rid="B12">Crans et al., 2018</xref>; <xref ref-type="bibr" rid="B11">2019</xref>; <xref ref-type="bibr" rid="B42">Selman et al., 2018</xref>; <xref ref-type="bibr" rid="B4">Assey and Mgohamwende, 2020</xref>; <xref ref-type="bibr" rid="B49">Suma et al., 2020</xref>). Vanadium can exist in many oxidation states; therefore, vanadium complexes are attractive to researchers for their promising biological activities. Several reports are on synthesizing vanadium complexes with different ligands to determine their magnetic, antidiabetic, antioxidant, and catalytic properties (<xref ref-type="bibr" rid="B11">Crans et al., 2019</xref>; <xref ref-type="bibr" rid="B4">Assey and Mgohamwende, 2020</xref>). However, vanadium and chromium-based complexes&#x2019; antibacterial and anticancer activity is rarely studied (<xref ref-type="bibr" rid="B45">Singh and Gupta, 2008</xref>; <xref ref-type="bibr" rid="B2">Al-Hazmi et al., 2020</xref>).</p>
<p>Meanwhile, the global rise of microbial resistance to antibiotics has become a major public health concern. Bacteria have developed mechanisms to resist the effects of almost all available antibiotics, resulting in increased morbidity and mortality from life-threatening infections. This scenario presents a major challenge, particularly for hospitalized patients more susceptible to such infections (<xref ref-type="bibr" rid="B19">Karata&#x15f; et al., 2021</xref>). In this context, nanotechnology has emerged as a potential alternative to conventional antimicrobials, as it offers unique opportunities for the development of nano products that can be utilized in the prevention, diagnosis, and targeted delivery of drugs (<xref ref-type="bibr" rid="B44">Shu et al., 2017</xref>; <xref ref-type="bibr" rid="B13">de Oliveira et al., 2020</xref>). By harnessing the properties of nanoparticles, such as their high surface area and reactivity, nanotechnology enables the creation of novel antimicrobial solutions. These nanoproducts have shown promising results in combating drug-resistant microorganisms and addressing the limitations of traditional antibiotics. Likewise, colon and cervical cancer are among the significant global health concerns, estimating 1.08 million new cases in 2020 for colon cancer alone (<xref ref-type="bibr" rid="B50">Sun et al., 2018</xref>; <xref ref-type="bibr" rid="B26">Mohanty et al., 2019</xref>). Current treatment options for cancer, including surgery, chemotherapy, radiotherapy, and immunotherapy, have limitations in effective metastasis and inhibiting tumor growth (<xref ref-type="bibr" rid="B25">Miller et al., 2019</xref>). Furthermore, prolonged consumption of chemotherapeutic drugs often leads to adverse side effects that could be life-threatening and painful for patients.</p>
<p>Consequently, there is a growing interest in developing innovative methods for controlling and treating cancer cells that are precise in their delivery and have fewer adverse effects. Nanotechnology offers promising approaches in this regard. By utilizing nanoparticles, it is possible to achieve targeted drug delivery, enhance the efficacy of cancer treatments, and minimize the side effects associated with conventional therapies (<xref ref-type="bibr" rid="B41">Schirrmacher, 2019</xref>).</p>
<p>Therefore, the convergence of nanotechnology and biomedical research has opened up new avenues for addressing the challenges posed by microbial resistance and cancer treatment. In this context, exploring metal-based nanoparticles, such as Zinc Chromium vanadate nanoparticles (VCrZnO4 NPs), holds excellent promise. VCrZnO4 NPs exceptional physical and chemical properties make them suitable candidates for antibacterial and anticancer applications (<xref ref-type="bibr" rid="B12">Crans et al., 2018</xref>; <xref ref-type="bibr" rid="B4">Assey and Mgohamwende, 2020</xref>; <xref ref-type="bibr" rid="B49">Suma et al., 2020</xref>). By bridging the knowledge gap and advancing our understanding of the biological activities of vanadium and chromium-based complexes, this study presents an innovative approach for synthesizing VCrZnO4 NPs using a one-pot solvothermal reaction with tetramethylammonium hydroxide (TMAOH) as both a reducing agent and a structure-directing agent. Notably, using TMAOH, uncommon in Zn metalate preparation, allows for the direct separation of the crystalline phase from the reaction solution, eliminating the need for an annealing step. Our research aims to shed light on the potential applications of VCrZnO4 NPs in combating microbial resistance and improving cancer treatment strategies. By exploring the unique properties of these nanoparticles, the study aims to contribute to the advancement of nanomedicine and bridge the knowledge gap regarding the biological activities of vanadium and chromium-based complexes in the realms of antibacterial and anticancer research. This exploration will not only enhance our understanding of the potential applications of VCrZnO4 nanoparticles but may also facilitate the advancement of nanomedicine. The findings of this study may pave the way for the development of more effective and targeted approaches in the fields of antibacterial treatments and anticancer therapies.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Synthesis</title>
<p>ZnCrVO4 NPs were prepared by mixing 2&#xa0;mmol of each CrCl3.6H2O (0.533&#xa0;g), VCl3 (0.314&#xa0;g), and Zn(CH3COO)2&#xb7;2H2O (0.44&#xa0;g), with 140&#xa0;mL of DI water in a 200&#xa0;mL Teflon-lined container before dropping 10&#xa0;mL of tetramethylammonium hydroxide (TMAOH) solution of 25&#xa0;wt% in H2O to the mixture. Then, the container was closed and tightly sealed into a stainless-steel autoclave and placed in a preheated oven at 200&#xb0;C for 48&#xa0;H. After cooling to room temperature, the precipitated dark grey NPs were separated from the solution by centrifuging and washing with DI water several times until a clear solution was obtained. The sample was washed with absolute ethanol, dried with diethyl ether, and placed in a vacuum oven at 80&#xb0;C overnight. The yield of the prepared NPs after the washing and drying process was approximately 98%, which confirms that the starting materials reacted completely under the specified conditions. <xref ref-type="fig" rid="F1">Figure 1</xref> illustrates the synthesis protocol for ZnCrVO4 nanoparticles (NPs) with antibacterial and anticancer activities.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Schematic representation of the synthesis protocol for ZnCrVO4 nanoparticles (NPs) with antibacterial and anticancer activities.</p>
</caption>
<graphic xlink:href="fphar-14-1213824-g001.tif"/>
</fig>
</sec>
<sec id="s2-2">
<title>2.2 Characterization</title>
<p>The method employed in this study involved several characterization techniques to analyze the Zinc Chromium vanadate nanoparticles (VCrZnO4 NPs). Powder X-Ray Diffraction (PXRD) analysis was conducted using a Rigaku Benchtop Miniflex X-ray powder diffractometer equipped with a Cu K&#x3b1; radiation generator. The measurement was carried out in a room, scanning the 2&#x3b8; range of 20&#x2013;70&#xb0; with a step size of 0.05, allowing for the determination of the crystalline structure of the nanoparticles. High-resolution transmission electron microscopy (HRTEM) imaging was performed using a TEM instrument, specifically the FEI Titan 80&#x2013;300&#xa0;kV FEGS/TEM. This technique provided detailed images of the nanoparticles at high magnification, allowing for the examination of their morphology and structure. The HRTEM analysis was coupled with Energy-dispersive X-ray spectroscopy (EDX) for elemental mapping, enabling the identification and spatial distribution of different elements within the nanoparticles.</p>
<p>Furthermore, X-ray photoelectron spectroscopy (XPS) analysis was carried out using a Kratos Axis Ultra instrument, equipped with a monochromatic X-ray source (Al K&#x3b1;). The XPS analysis was conducted under an extremely high vacuum (10&#x2013;9&#xa0;mbar) and provided valuable information about the chemical composition and surface properties of the nanoparticles. Together, these characterization techniques offered a comprehensive analysis of the structural, morphological, and elemental characteristics of the VCrZnO4 NPs, contributing to a better understanding of their properties and potential applications (<xref ref-type="bibr" rid="B5">Aygar et al., 2015</xref>).</p>
</sec>
<sec id="s2-3">
<title>2.3 Antibacterial studies</title>
<sec id="s2-3-1">
<title>2.3.1 Inoculum preparation</title>
<p>For the antibacterial studies, Gram-negative bacteria were selected as the target pathogens. Specifically, <italic>Shigella flexneri</italic> (ATCC12022) (<xref ref-type="bibr" rid="B31">Philpott et al., 2000</xref>), <italic>Salmonella choleraesuis</italic> (ATCC10708) (<xref ref-type="bibr" rid="B8">Chiu et al., 2004</xref>), and <italic>Escherichia coli</italic> (ATCC352118) (<xref ref-type="bibr" rid="B18">Kaper et al., 2004</xref>) were chosen as representative human pathogens. These bacteria were cultured in Nutrient broth (NB) at 37&#xb0;C &#xb1; 2&#xb0;C for an overnight incubation period (<xref ref-type="bibr" rid="B36">Rather et al., 2023</xref>). Subsequently, during the exponential growth phase, the bacterial cells were harvested. To prepare the cells for further antibacterial analysis, they were washed with PBS and suspended in the same buffer. The concentration of the bacterial suspension was adjusted to 1 &#xd7; 10<sup>6</sup>&#xa0;CFU/mL, ensuring a standardized inoculum size for the subsequent antibacterial assays. This standardized approach enabled accurate and consistent assessment of the antibacterial activity of the Zinc Chromium vanadate nanoparticles against these specific Gram-negative bacteria.</p>
</sec>
<sec id="s2-3-2">
<title>2.3.2 Broth dilution method</title>
<p>The broth dilution technique was used to evaluate the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of the synthesized nanomaterial VCrZnO4 using the same method described elsewhere (<xref ref-type="bibr" rid="B52">Wijesundara et al., 2021</xref>; <xref ref-type="bibr" rid="B35">Rather et al., 2022a</xref>). Samples were sonicated and diluted with Mueller Hinton broth (MHB) to obtain homogenized broth suspension at 16, 8, 4, and 2&#xa0;mg/mL. The adjusted inoculum was added to the prepared broth solution at 1 &#xd7; 10<sup>6</sup>&#xa0;CFU/mL. Bacteria were incubated at 37&#xb0;C &#xb1; 2 &#xb0;C for 18&#x2013;20&#xa0;h. Control was taken as untreated bacteria under the same conditions. After incubation, antibacterial activity was determined by obtaining the MIC and MBC. Briefly, the aliquot of incubated bacterial suspension was streaked onto freshly prepared MHA plates, which were then incubated at 37&#xb0;C overnight. Then, the plates were observed, and <underline>t</underline>he MIC was taken as the concentration of the nanomaterial at which the 70%&#x2013;90% growth is inhibited, while the MBC was taken as the concentration at which no cell or less than 3&#xa0;cells were found (<xref ref-type="bibr" rid="B39">Rehman et al., 2019</xref>).</p>
</sec>
<sec id="s2-3-3">
<title>2.3.3 Morphogenesis of treated bacterial cells</title>
<p>Morphological changes in bacteria treated with VCrZnO4 were studied using scanning electron microscopy (SEM) (<xref ref-type="bibr" rid="B36">Rather et al., 2023</xref>). The representative concentration obtained as MIC was used to treat <italic>S. flexneri, S. cholerasuis</italic>, and <italic>E. coli</italic>, while untreated bacteria were used as a control. The cells were washed multiple times in PBS and then centrifuged to remove the residual medium. After that, the cells were fixed with 2.5% glutaraldehyde for 6&#xa0;h, followed by fixation with 1% osmium tetroxide for 1&#xa0;h. Next, the cells were dehydrated using varying concentrations of ethanol solution and again washed and suspended in PBS. Finally, the cells were placed on a stub and dried in a desiccator to complete the drying process. After gold coating, the samples were analyzed under SEM at 20&#xa0;kV using a scanning electron microscope (<xref ref-type="bibr" rid="B38">Rehman et al., 2020</xref>).</p>
</sec>
</sec>
<sec id="s2-4">
<title>2.4 Anticancer studies</title>
<sec id="s2-4-1">
<title>2.4.1 <italic>In vitro</italic> testing of cell viability by MTT assay</title>
<p>Human colorectal cancer cells were obtained from American Type Cell Culture ATCC, United States, and were used to study the viability of cancer cells mediated by nanoparticles VCrZnO4 (<xref ref-type="bibr" rid="B3">Alzahrani et al., 2022</xref>; <xref ref-type="bibr" rid="B37">Rather et al., 2022b</xref>). HEK-293 cells were also used as a control to ensure the effectiveness of the study. First, 96 well plates containing special DMEM media were seeded in a CO2 incubator and kept for 24&#xa0;h. To conduct the MTT assay, the nanocomposites VCrZnO4 were added to each well containing HCT-116, HELA, and HEK-293 cells in concentrations ranging from 2.0&#xa0;&#x3bc;g/mL to 75&#xa0;&#x3bc;g/mL for 48&#xa0;h. The control wells were not treated with nanoparticles VCrZnO4. After treatment, the cells were exposed to MTT (5.0&#xa0;mg/mL) for 4&#xa0;h, and the media was replaced with DMSO. The optical density (OD) of the cells was then measured at 570&#xa0;nm using a Plate Reader supplied by Bio-Tek Instruments, United States. The percentage of cell viability was calculated based on OD, and the data obtained from triplicates were statistically evaluated using GraphPad Version 6.0 Prism Software United States. Mean &#xb1; standard deviation values were presented in the graph (<xref ref-type="bibr" rid="B21">Khan et al., 2018</xref>).</p>
</sec>
<sec id="s2-4-2">
<title>2.4.2 Apoptotic DAPI staining</title>
<p>To examine the impact of nanocomposite VCrZnO4 on the nucleus of cancer HCT-116 and HELA cells, we stained cells with DAPI staining post-48-h treatment of nanoparticles VCrZnO4 with 60&#xa0;&#x3bc;g/mL. In brief, cells were treated with paraformaldehyde and labeled with DAPI dye. The blue, fluorescent staining was examined under a Confocal Scanning Microscope (Zeiss, Germany) (Zeiss, Germany) (<xref ref-type="bibr" rid="B21">Khan et al., 2018</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>3 Results and discussion</title>
<p>Structural and morphological studies of ZnVCrO<sub>4</sub> NPs have been conducted using various techniques, including PXRD SEM, TEM, and XPS. These studies have provided valuable insights into the crystal structure and morphology of this compound, which are essential for understanding its potential applications in various fields.</p>
<sec id="s3-1">
<title>3.1 Structural and morphological studies</title>
<p>The measured PXRD pattern for ZnVCrO<sub>4</sub> is displayed in <xref ref-type="fig" rid="F2">Figure 2</xref>. The plot shows the presence of only one crystalline phase corresponding to a cubic close-packed spinel structure. The lattice constant <italic>a</italic> was calculated through the most intense peak corresponding to (311) to be <italic>a</italic> &#x3d; 8.55&#xa0;&#xc5;.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>PXRD pattern for ZnCrVO<sub>4</sub> NPs recorded at room temperature.</p>
</caption>
<graphic xlink:href="fphar-14-1213824-g002.tif"/>
</fig>
<p>TEM images, captured in different resolutions, in <xref ref-type="fig" rid="F3">Figure 3</xref> show aggregation of nanoparticles with a size of &#x2c2; 20&#xa0;nm. The selected Area Electron Diffraction (SAED) has been used to confirm the crystallinity of the prepared NPs. The interplanar distance (<italic>d</italic>-spacing) was determined from the lattice fringes of the first diffraction ring. The calculated <italic>d</italic>-spacing is 4.94&#xa0;&#xc5;, corresponding to (111) plan of spinel lattice which agreed well with the PXRD analysis. <xref ref-type="fig" rid="F4">Figure 4</xref> shows the elemental mapping and EDX analysis for ZnVCrO<sub>4</sub> NPs, confirming the presence of the Zn, V, Cr, and O exclusively in the sample with the elemental ratio of &#x2248;1:1:1:4, respectively.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>TEM images and SEAD analysis for ZnCrVO<sub>4</sub> NPs.</p>
</caption>
<graphic xlink:href="fphar-14-1213824-g003.tif"/>
</fig>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>HAADF elemental mapping and EDX analysis for ZnCrVO<sub>4</sub> NPs.</p>
</caption>
<graphic xlink:href="fphar-14-1213824-g004.tif"/>
</fig>
<p>For the fourth identification and confirmation of phase purity, XPS analysis was performed on the prepared NPs. A survey scan for detecting all elements in the sample is shown in <xref ref-type="fig" rid="F5">Figure 5A</xref>.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>
<bold>(A)</bold> survey analysis, <bold>(B)</bold> narrow V 2p and O 1s XPS spectrum, <bold>(C)</bold> Cr 2p XPS spectrum and <bold>(D)</bold> Zn 2p XPS spectrum, for ZnCrVO<sub>4</sub> NPs.</p>
</caption>
<graphic xlink:href="fphar-14-1213824-g005.tif"/>
</fig>
<p>The narrow spectrum in <xref ref-type="fig" rid="F5">Figure 5B</xref> shows two peaks at 516.49 and 523.79&#xa0;eV with a spin splitting of 7.3&#xa0;eV belonging to V 2p<sub>3/2</sub> and V 2p<sub>1/2</sub>, respectively, of the V<sup>3&#x2b;</sup> oxidation state. (1-2) The asymmetric peak at 529.99&#xa0;eV is related to O 1s of the metal oxide onions. The Cr 2p XPS spectrum in <xref ref-type="fig" rid="F5">Figure 5C</xref> displays two peaks at 576.49 and 586.19&#xa0;eV related to Cr 2p<sub>3/2</sub> and Cr 2p<sub>1/2</sub>, respectively, for the Cr<sup>3&#x2b;</sup> oxidation state. (3). The Zn 2p XPS spectrum in <xref ref-type="fig" rid="F5">Figure 5D</xref> has two sharp peaks at 1021.2 Ev and 1044.2 Ev belonging to Zn 2p<sub>3/2</sub> and Zn 2p<sub>1/2</sub>, respectively, for the Zn<sup>2&#x2b;</sup> oxidation state. (1-3) The XPS result confirms the purity and the chemical formula of the prepared NPs as Zn<sup>2&#x2b;</sup>(VCr)<sup>6&#x2b;</sup>O<sub>4</sub>.</p>
</sec>
<sec id="s3-2">
<title>3.2 Antibacterial studies</title>
<sec id="s3-2-1">
<title>3.2.1 MIC/MBC</title>
<p>Determination of the antibacterial activity of Zinc Chromium vanadate VCrZnO4 through the broth dilution method obtained the growth inhibition of all the bacteria tested. The antibacterial activities were examined using three gram-negative bacteria (<italic>S. flexneri</italic>, <italic>S. cholerasuis</italic>, and <italic>E. coli</italic>). Bacteria were treated with different concentrations of VCrZnO4. It was observed that with increasing nanomaterial concentration, the MIC/MBC was reduced, indicating the effect of nanomaterial on the tested bacteria. As shown in <xref ref-type="fig" rid="F6">Figure 6</xref>, the MIC/MBC for <italic>S. flexneri</italic>, <italic>S. cholerasuis</italic>, and <italic>E. col</italic> was 1/2, 2/4, and 16/16&#xa0;mg/mL, respectively. This indicated variation in the inhibitory effect. The presented results summarize the effect on bacteria growth when treated with VCrZnO4 compared to the untreated bacteria grown under the same conditions on the gram-negative bacteria. However, <italic>E. col</italic>i had a higher MBC and MBC than <italic>S. flexneri and S. cholerasuis</italic>. The nanomaterial overall showed the inhibition of growth with all three gram-negative bacteria, mostly water-dwelling organisms responsible for many enteric infections.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Photo depicting the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of the tested bacteria. Each number on photo represents a different concentration as follows: (1) 16&#xa0;mg/mL, (2) 8&#xa0;mg/mL, (3) 4&#xa0;mg/mL, (4) 2&#xa0;mg/mL, (5) 1&#xa0;mg/mL, (6) 0.5&#xa0;mg/mL, (7) 0.25: mg/mL, <bold>(C)</bold> control group of untreated bacteria.</p>
</caption>
<graphic xlink:href="fphar-14-1213824-g006.tif"/>
</fig>
<p>The remarkable versatility of nanoparticles (NPs) as antibacterial agents cannot be overstated. These tiny warriors have been shown to combat a wide range of Gram-positive and Gram-negative bacteria with unparalleled efficiency. For example, previously, ZnO NPs have been observed wielding their antimicrobial prowess against <italic>Staphylococcus aureus</italic>. At the same time, the valiant Ag NPs demonstrate a concentration-dependent capacity to vanquish foes such as <italic>Escherichia coli</italic> and <italic>Pseudomonas aeruginosa</italic> (<xref ref-type="bibr" rid="B34">Ramalingam et al., 2016</xref>)<italic>.</italic> The remarkable antimicrobial properties of these microscopic wonders are a testament to modern science and technology.</p>
<p>Several studies have assessed the antibacterial properties of ZnO-Nps using the broth dilution method against a range of bacterial strains, including <italic>Pseudomonas aeruginosa</italic>, <italic>Staphylococcus aureus</italic>, <italic>Escherichia coli</italic>, and <italic>Klebsiella pneumoniae</italic> (<xref ref-type="bibr" rid="B54">Yamamoto, 2001</xref>; <xref ref-type="bibr" rid="B33">Raghupathi et al., 2011</xref>; <xref ref-type="bibr" rid="B46">Sirelkhatim et al., 2015</xref>; <xref ref-type="bibr" rid="B34">Ramalingam et al., 2016</xref>; <xref ref-type="bibr" rid="B14">Fakhroueian et al., 2019</xref>). The observed results indicate that direct contact of ZnO-NPs with cell walls leads to the destruction of bacterial cell integrity (<xref ref-type="bibr" rid="B1">Adams et al., 2006</xref>; <xref ref-type="bibr" rid="B7">Brayner et al., 2006</xref>; <xref ref-type="bibr" rid="B57">Zhang et al., 2007</xref>; <xref ref-type="bibr" rid="B44">Shu et al., 2017</xref>), release of antimicrobial ions primarily Zn2&#x2b; ions (<xref ref-type="bibr" rid="B20">Kasemets et al., 2009</xref>; <xref ref-type="bibr" rid="B23">Li et al., 2011</xref>), and the formation of ROS (<xref ref-type="bibr" rid="B40">Sawai et al., 1998</xref>; <xref ref-type="bibr" rid="B56">Zhang et al., 2008</xref>; <xref ref-type="bibr" rid="B16">Jalal et al., 2010</xref>). The antibacterial activity of nanoparticles has been attributed to their unique structural and chemical properties, including its high surface area, porous structure, and metal ions that can interact with bacterial cell membranes and disrupt their function. The exact mechanism of the antibacterial action of nanoparticles is still under investigation. However, these findings suggest these nanoparticles have potential as a new antibacterial agent and could be further explored for their applications in medicine and healthcare.</p>
</sec>
<sec id="s3-2-2">
<title>3.2.2 Morphogenesis of treated bacterial cells</title>
<p>The concentration chosen for this study was the MIC concentration of the nanomaterial for each strain. With the aid of a control experiment, i.e., untreated bacteria, the treated <italic>S. flexneri</italic>, <italic>S. cholerasuis</italic>, and <italic>E. coli</italic> showed the most abnormal appearance, as seen in <xref ref-type="fig" rid="F7">Figure 7</xref>. The control cells displayed normal shape with intact cell surfaces (<xref ref-type="fig" rid="F7">Figure 7A</xref>.). The bacteria displayed deformations ranging from mild to severe after being treated with Zinc Chromium vanadate VCrZnO4. Observations made in <xref ref-type="fig" rid="F7">Figure 7B</xref> exhibit a remarkable distortion of <italic>S. flexneri</italic> cells, including severe disruption of the cell membrane. <italic>S. cholerasuis</italic> and <italic>E. coli</italic> also displayed comparable aberrations, where the once regular rod-shaped morphology was significantly compromised, manifesting in irregular shape and size, coupled with marked damage to the cellular surface. A possible mechanism for inhibiting bacterial proliferation is the attachment of nanomaterial to the bacterial surface after it encounters the nanomaterial (<xref ref-type="bibr" rid="B44">Shu et al., 2017</xref>). By attaching nanomaterial to the surface of the bacterial cell, membrane integrity is compromised, ultimately leading to cell death. Reactive oxygen species (ROS) generated by nanomaterial attachment and bacterial cells are also considered crucial in bacterial cell morphogenesis.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Morphological changes in three bacterial cells following treatment with nanoparticles VCrZnO<sub>4</sub> nanoparticles. <bold>(A)</bold> Control group of untreated cells. <bold>(B)</bold> Cells treated with VCrZnO4 nanoparticles at the selected minimum inhibitory concentration (MIC).</p>
</caption>
<graphic xlink:href="fphar-14-1213824-g007.tif"/>
</fig>
<p>Several studies have shown that when bacteria are treated with zinc oxide nanoparticles, it can cause damage to their cell walls and membranes, leading to changes in their morphology and, ultimately, cell death. For instance, a study by <xref ref-type="bibr" rid="B64">Li et al. (2010)</xref> investigated the effect of zinc oxide nanoparticles on the growth of <italic>Escherichia coli</italic> bacteria (<xref ref-type="bibr" rid="B23">Li et al., 2011</xref>). The researchers found that even at low concentrations, zinc oxide nanoparticles could inhibit the growth of the bacteria, and at higher concentrations, it caused significant damage to the bacterial cells, including changes in their shape and size. While Zinc Chromium vanadate s has shown promising results as an antimicrobial agent, it is important to note that its use may negatively affect other organisms, including beneficial bacteria and humans. The Zinc Chromium vanadate nanoparticles could be toxic to certain types of beneficial bacteria found in the gut, potentially leading to disruptions in the microbiome and associated health problems (<xref ref-type="bibr" rid="B55">Yoo et al., 2021</xref>). Therefore, while Zinc Chromium vanadate shows promise as an antimicrobial agent, further research is needed to fully understand its potential benefits and risks, as well as its mechanisms of action and potential applications in medicine and industry.</p>
</sec>
</sec>
<sec id="s3-3">
<title>3.3 Anticancer assay</title>
<sec id="s3-3-1">
<title>3.3.1 Cell viability by MTT assay</title>
<p>The impact of nanoparticles VCrZnO<sub>4</sub> on HCT-116 and HELA cells was examined. Post 48&#xa0;h; we found a significant decrease in cancer cells post-treatment of nanoparticles VCrZnO4 in both HCT-116 and HELA cells (<xref ref-type="fig" rid="F8">Figure 8</xref>
<italic>)</italic>. While the treatment of nanoparticles VCrZnO showed better and stronger inhibitory action on HELA cells than on HCT-116 cells (<xref ref-type="fig" rid="F8">Figure 8</xref>). The treatment of nanoparticles VCrZnO4 on HEK-293 cells showed a decline in the normal cell population. However, the treatment of nanoparticles produced less cytotoxicity on normal HEK-293 cells than on HCT-116 and HeLa cells (<xref ref-type="fig" rid="F8">Figure 8</xref>).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>
<xref ref-type="fig" rid="F8">Figure 8</xref>: Impact of VCrZnO4 nanoparticle treatment on the viability of HCT-116, HELA, and HEK-293 cells after 48&#xa0;h of treatment. The graph depicts the observed effects on cell viability. &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-14-1213824-g008.tif"/>
</fig>
<p>Our results suggest that VCrZnO4 nanoparticles exhibit significant cytotoxicity against HCT-116 and HELA cells. Many studies have shown that nanomaterials and biomaterials produce anticancer activities. For example, ZnO nanoparticles showed a dynamic cytotoxic effect in cervical carcinoma cells, and the impact of ZnO nanoparticles on cancer cells was due to the induction of apoptosis through increased intracellular ROS levels (<xref ref-type="bibr" rid="B59">Pandurangan et al., 2016</xref>). In another study, the effect of ZnO nanoparticles was studied against small-cell lung cancer where ZnO nanoparticles induced cancer cell death by activating reactive oxygen species and DNA leakage from nuclei and also observed the upregulation of apoptotic gene expression (<xref ref-type="bibr" rid="B60">Tanino et al., 2020</xref>). In another study, thymoquinone-conjugated ZnO nanoparticles mediated cytotoxicity and anticancer action on breast cancer cells (<xref ref-type="bibr" rid="B61">Banupriya et al., 2022</xref>). ZnO nanoparticles conjugated with N-succinyl chitosan showed strong anticancer activities on breast cancer cells (MDA-MB-231) by inducing apoptotic action (<xref ref-type="bibr" rid="B62">Ghaffari et al., 2020</xref>). The treatment of ZnO nanoparticles containing Oxaliplatin via polymerization showed strong anticancer action on colorectal cancer cells, as examined in both <italic>in vitro</italic> studies and <italic>in vivo</italic> mouse models (<xref ref-type="bibr" rid="B63">Alavi et al., 2023</xref>). In addition, the treatment of pure ZnO nanoparticles and doped with molybdenum and graphene oxide nanoparticles showed anticancer activity on the human colon (HCT116) and breast (MCF7) cancer cells, and anticancer action was mediated through reactive oxygen species, p53, and the caspase-3 pathway (<xref ref-type="bibr" rid="B58">Ahamed et al., 2022</xref>). Applying chromium oxide (CrO) nanoparticles also exhibited anticancer activity on MCF-7 cells, HepG2, and HUH-7 cancer cells (<xref ref-type="bibr" rid="B15">Jermy et al., 2019</xref>; <xref ref-type="bibr" rid="B24">Li et al., 2020</xref>). Besides, there have been numerous other studies that have shown that both nanomaterials and biomaterials can produce anticancer activities. These materials can be used in various ways to help prevent, diagnose, and treat cancer, and they have shown promising results in preclinical and clinical studies (<xref ref-type="bibr" rid="B10">Connor et al., 2005</xref>). Researchers used gold nanoparticles to target and destroy tumor cells in mice (<xref ref-type="bibr" rid="B30">Peng et al., 2019</xref>). The result underpins that the nanoparticles could deliver a drug directly to the tumor cells, significantly reducing tumor growth and increasing survival rates in the mice (<xref ref-type="bibr" rid="B30">Peng et al., 2019</xref>). The use of hydrogel nanoparticles could be used to deliver a drug directly to the tumor cells, resulting in significantly reduced tumor growth and increased survival rates in mice (<xref ref-type="bibr" rid="B6">Biondi et al., 2015</xref>; <xref ref-type="bibr" rid="B28">Nolan et al., 2018</xref>; <xref ref-type="bibr" rid="B32">Rafieian et al., 2019</xref>; <xref ref-type="bibr" rid="B17">Jiang et al., 2020</xref>; <xref ref-type="bibr" rid="B27">Nadtoka et al., 2020</xref>; <xref ref-type="bibr" rid="B47">Stojkovska et al., 2020</xref>; <xref ref-type="bibr" rid="B9">Clasky et al., 2021</xref>; <xref ref-type="bibr" rid="B48">Sulaiman et al., 2021</xref>; <xref ref-type="bibr" rid="B29">Nunes et al., 2022</xref>).</p>
</sec>
<sec id="s3-3-2">
<title>3.3.2 Apoptotic death of cancer cells as revealed by DAPI staining</title>
<p>In order to better understand the cause of cancer cell death, we examined both HCT-116 and HELA cells using DAPI (4&#x2032;,6-diamidino-2-phenylindole), a blue-fluorescent DNA stain used to identify apoptosis. <xref ref-type="fig" rid="F9">Figures 9A, B</xref> depict that administering VCrZnO4 NPs decreases HCT-116 colon cancer cell death. Similarly; <xref ref-type="fig" rid="F9">Figures 9B, D</xref> displayed a reduction in cell death for HELA cervical cancer cells. Notably, post-treatment with VCrZnO4 nanoparticles, we observed chromatin condensation and the presence of apoptotic bodies in HCT-166 cells (<xref ref-type="fig" rid="F9">Figures 9B,D</xref>). In contract the nuclei in the control group exhibited no discernible structural or aesthetic changes (<xref ref-type="fig" rid="F9">Figures 9A,C</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Apoptotic death of cancer cells revealed by DAPI staining. <bold>(A)</bold> Control cells with normal morphology and intact, healthy cells. <bold>(B)</bold> Impact of VCrZnO4 nanoparticles on colon cancer cells (HCT-116) after 48&#xa0;h of treatment (60&#xa0;&#x3bc;g/mL). <bold>(C)</bold> Control cells with normal morphology and intact, healthy cells. <bold>(D)</bold> Impact of VCrZnO4 nanoparticles on HELA cancer cells. Arrows indicate observed chromatin condensation, nuclear augmentation, and formation of apoptotic bodies.</p>
</caption>
<graphic xlink:href="fphar-14-1213824-g009.tif"/>
</fig>
<p>In <xref ref-type="fig" rid="F9">Figure 9B</xref>, VCrZnO4 nanoparticles are shown in response to colon cancer cells (HCT-116), with <xref ref-type="fig" rid="F9">Figure 9A</xref> representing the control cells with normal morphology and intact and healthy cells; and 8b representing the responses after 48&#xa0;h of treatment (60 ug/mL). <xref ref-type="fig" rid="F9">Figures 9D&#x2013;F</xref> show the impact of nanoparticles VCrZnO4 on HELA cancer cells, with <xref ref-type="fig" rid="F9">Figure 9B</xref> depicting the control cells with normal morphology and intact structure. Arrows in the figures highlight observed phenomena such as chromatin condensation, nuclear augmentation, and the formation of apoptotic bodies. In addition, IC<sub>50</sub> values have also been calculated and are shown in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Calculation of IC<sub>50</sub> after treatment of VCrZnO<sub>4</sub>.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left"/>
<th colspan="3" align="left">IC<sub>50</sub> &#xb5;g/mL</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left"/>
<td align="left">HCT-116</td>
<td align="left">HELA</td>
<td align="left">HEK-293</td>
</tr>
<tr>
<td align="left">VCrZnO4</td>
<td align="left">38.50 &#x2b; 3.50</td>
<td align="left">42.25 &#x2b; 4.15</td>
<td align="left">43.55 &#x2b; 4.85</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Of note, nanoparticles have also shown promising potential in inducing apoptotic death of cancer cells. Apoptosis induction in cancer cells is a promising approach for cancer therapy as it selectively targets and eliminates cancer cells while sparing normal cells. Many studies suggest nanocomposites as a promising approach to kill cancer cells. Gold nanoparticles decorated with polypyrrole induced apoptotic death in breast cancer cells. The study investigated the potential use of polypyrrole-coated gold nanoparticles as a photothermal therapy for breast cancer cells (<xref ref-type="bibr" rid="B50">Sun et al., 2018</xref>). The researchers found that the nanoparticles could selectively target breast cancer cells and induce apoptotic cell death upon exposure to near-infrared laser irradiation. The study suggested that polypyrrole-coated gold nanoparticles could be a promising and effective therapy for breast cancer. Further, zinc oxide nanoparticles also induced apoptotic death in prostate cancer cells by activating the caspase pathway. In addition, silver nanoparticles coated with graphene oxide or reduced graphene oxide could be a potential therapeutic agent for lung cancer (<xref ref-type="bibr" rid="B53">Yadav et al., 2022</xref>). These results have shown promising potential in inducing apoptosis of cancer cells, which could be a selective and practical approach for cancer therapy. Further research is needed to evaluate their safety and efficacy in clinical settings.</p>
</sec>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>4 Conclusion</title>
<p>This study successfully synthesized VCrZnO4 nanoparticles and investigated their antibacterial and anticancer properties. The comprehensive analysis using various characterization techniques provided insights into the structural and morphological characteristics of the nanomaterials. While the synthesized nanoparticles showed potential as a dual solution for eradicating waterborne<italic>Enterobacteriaceae</italic> and fighting cancer, further research is needed to confirm their effectiveness in treating bacterial infections and cancers through <italic>in vivo</italic> studies. Moreover, it would be valuable for future investigations to explore their potential in areas like drug delivery and wound healing, assessing long-term safety and effectiveness, and evaluating their efficacy against cancer cells. These findings contribute to the advancement of nanomedicine and highlight the potential of VCrZnO4 nanoparticles as promising candidates for antibacterial and anticancer applications, paving the way for developing more effective therapeutic strategies.</p>
</sec>
<sec id="s5">
<title>5 Possible limitations of the study</title>
<p>While the study on Zinc Chromium vanadate nanoparticles (VCrZnO4 NPs) holds promise for potential antibacterial and anticancer applications, it is important to acknowledge several limitations. Firstly, the study was conducted solely <italic>in vitro</italic>, highlighting the need for further research to assess the efficacy of the NPs <italic>in vivo</italic>. Secondly, the study only tested the NPs against a limited number of bacterial strains and cancer cells. Additional testing against a broader range of pathogens and cancer cell lines is necessary to confirm the general applicability of the NPs. Thirdly, the long-term effects of exposure to the NPs are still unknown, and future studies need to explore the potential toxicity of VCrZnO4 NPs on human cells. Finally, the synthesis of VCrZnO4 NPs using a one-pot solvothermal method may be challenging for large-scale production, limiting the nanomaterials&#x2019; practical applications. Addressing these limitations through further research will be instrumental in realizing the full potential of VCrZnO4 Nps as versatile nanomaterials for antibacterial and anticancer therapies.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>Conceptualization, SR and FA; methodology, SR, FA, SA, LA, and MA; software, SSA; validation, FK, FA, SR, and MA formal analysis, FA; investigation, SA; resources, SSA; data curation SR and FA; writing&#x2014;original draft preparation, SR and IR; writing&#x2014;review and editing, SR, JS, and IR; visualization, SR and JS; supervision, FK; project administration, SR; funding acquisition, IR and JS. All authors have read and agreed to the published version of the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This research work was funded by Institutional Fund Projects under grant no. (IFPIP: 98-130-1443). The authors gratefully acknowledge technical and financial support provided by the Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia.</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>L. K.</given-names>
</name>
<name>
<surname>Lyon</surname>
<given-names>D. Y.</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>P. J. J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Comparative eco-toxicity of nanoscale TiO2, SiO2, and ZnO water suspensions</article-title>. <source>Water Res.</source> <volume>40</volume>, <fpage>3527</fpage>&#x2013;<lpage>3532</lpage>. <pub-id pub-id-type="doi">10.1016/j.watres.2006.08.004</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahamed</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akhtar</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M. A. M.</given-names>
</name>
<name>
<surname>El-Metwaly</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Alhadlaq</surname>
<given-names>H. A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Enhanced anticancer performance of eco-friendly-prepared Mo-ZnO/RGO nanocomposites: role of oxidative stress and apoptosis</article-title>. <source>ACS Omega</source> <volume>7</volume>, <fpage>7103&#x2013;7115</fpage>. <pub-id pub-id-type="doi">10.1021/acsomega.1c06789</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alavi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Maghami</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pakdel</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Rezaei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Avan</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The advance anticancer role of polymeric core-shell ZnO nanoparticles containing oxaliplatin in colorectal cancer</article-title>. <source>J. Biochem. Mol. Toxicol.</source> <volume>37 (5)</volume>, <fpage>e23325</fpage>. <pub-id pub-id-type="doi">10.1002/jbt.23325</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Hazmi</surname>
<given-names>G. A. A.</given-names>
</name>
<name>
<surname>Abou-Melha</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Althagafi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>El-Metwaly</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Shaaban</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Abdul Galil</surname>
<given-names>M. S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Synthesis and structural characterization of oxovanadium(IV) complexes of dimedone derivatives</article-title>. <source>Appl. Organomet. Chem.</source> <volume>34</volume>, <fpage>e5672</fpage>. <pub-id pub-id-type="doi">10.1002/aoc.5672</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alzahrani</surname>
<given-names>O. R.</given-names>
</name>
<name>
<surname>Hawsawi</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Alanazi</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Alatwi</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>Rather</surname>
<given-names>I. A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>
<italic>In vitro</italic> evaluation of <italic>Leuconostoc mesenteroides</italic> cell-free-supernatant GBUT-21 against SARS-CoV-2</article-title>. <source>Vaccines (Basel)</source> <volume>10</volume>, <fpage>1581</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines10101581</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Assey</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Mgohamwende</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A review of Titanium, Vanadium and Chromium transition metal Schiff base complexes with biological and catalytic activities</article-title>. <source>Pharm. Pharmacol. Int. J.</source> <volume>8</volume>, <fpage>136</fpage>&#x2013;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.15406/ppij.2020.08.00289</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aygar</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kaya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>&#xd6;zkan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kocabiyik</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Volkan</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Preparation of silica coated cobalt ferrite magnetic nanoparticles for the purification of histidine-tagged proteins</article-title>. <source>J. Phys. Chem. Solids</source> <volume>87</volume>, <fpage>64</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpcs.2015.08.005</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banupriya</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Kavithaa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Poornima</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sumathi</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Mechanistic study on thymoquinone conjugated ZnO nanoparticles mediated cytotoxicity and anticancer activity in triple-negative breast cancer cells</article-title>. <source>Anticancer Agents Med. Chem.</source> <volume>22 (2)</volume>, <fpage>313</fpage>&#x2013;<lpage>327</lpage>. <pub-id pub-id-type="doi">10.2174/1871520621666210412104731</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biondi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borzacchiello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mayol</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ambrosio</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Nanoparticle-integrated hydrogels as multifunctional composite materials for biomedical applications</article-title>. <source>Gels</source> <volume>1</volume>, <fpage>162</fpage>&#x2013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.3390/gels1020162</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brayner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ferrari-Iliou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brivois</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Djediat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Fi&#xe9;vet</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Toxicological impact studies based on <italic>Escherichia coli</italic> bacteria in ultrafine ZnO nanoparticles colloidal medium</article-title>. <source>Nano Lett.</source> <volume>6</volume>, <fpage>866</fpage>&#x2013;<lpage>870</lpage>. <pub-id pub-id-type="doi">10.1021/nl052326h</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiu</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>
<italic>Salmonella enterica</italic> serotype choleraesuis: Epidemiology, pathogenesis, clinical disease, and treatment</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>17</volume>, <fpage>311</fpage>&#x2013;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.17.2.311-322.2004</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clasky</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Watchorn</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P. Z.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>F. X.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>From prevention to diagnosis and treatment: Biomedical applications of metal nanoparticle-hydrogel composites</article-title>. <source>Acta Biomater.</source> <volume>122</volume>, <fpage>1</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2020.12.030</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connor</surname>
<given-names>E. E.</given-names>
</name>
<name>
<surname>Mwamuka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gole</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Wyatt</surname>
<given-names>M. D.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity</article-title>. <source>Small</source> <volume>1</volume>, <fpage>325</fpage>&#x2013;<lpage>327</lpage>. <pub-id pub-id-type="doi">10.1002/smll.200400093</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crans</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>L. R.</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Posner</surname>
<given-names>B. I.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Developing vanadium as an antidiabetic or anticancer drug: A clinical and historical perspective</article-title>. <source>Met. Ions Life Sci.</source> <volume>19</volume>, <fpage>359</fpage>&#x2013;<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1515/9783110527872-014</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crans</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Haase</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Health benefits of vanadium and its potential as an anticancer agent</article-title>. <source>Met. Ions Life Sci.</source> <volume>18</volume>, <fpage>437</fpage>&#x2013;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1515/9783110470734-015</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Oliveira</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Oshiro-Junior</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Dantas</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>da Fons&#xea;ca</surname>
<given-names>N. F.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>J. V. B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>An overview of the antimicrobial activity of polymeric nanoparticles against Enterobacteriaceae</article-title>. <source>Curr. Pharm. Des.</source> <volume>27</volume>, <fpage>1311</fpage>&#x2013;<lpage>1322</lpage>. <pub-id pub-id-type="doi">10.2174/1381612826666201029095327</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fakhroueian</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Katouzian</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Esmaeilzadeh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Moradi Bidhendi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Esmaeilzadeh</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Enhanced engineered ZnO nanostructures and their antibacterial activity against urinary, gastrointestinal, respiratory and dermal genital infections</article-title>. <source>Appl. Nanosci. Switz.</source> <volume>9</volume>, <fpage>1759</fpage>&#x2013;<lpage>1773</lpage>. <pub-id pub-id-type="doi">10.1007/s13204-019-00996-5</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghaffari</surname>
<given-names>S.-B.</given-names>
</name>
<name>
<surname>Sarrafzadeh</surname>
<given-names>M.-H.</given-names>
</name>
<name>
<surname>Salami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khorramizadeh</surname>
<given-names>M. R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A pH-sensitive delivery system based on N-succinyl chitosan-ZnO nanoparticles for improving antibacterial and anticancer activities of curcumin</article-title>. <source>Int. J. Biol. Macromol.</source> <volume>151</volume>, <fpage>428&#x2013;440</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.02.141</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jermy</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Alomari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ravinayagam</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Almofty</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Akhtar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Borgio</surname>
<given-names>J. F.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>SPIONs/3D SiSBA-16 based Multifunctional Nanoformulation for target specific cisplatin release in colon and cervical cancer cell lines</article-title>. <source>Sci. Rep.</source> <volume>9</volume>, <fpage>14523</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-51051-w</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jalal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Goharshadi</surname>
<given-names>E. K.</given-names>
</name>
<name>
<surname>Abareshi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moosavi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yousefi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nancarrow</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>ZnO nanofluids: Green synthesis, characterization, and antibacterial activity</article-title>. <source>Mater Chem. Phys.</source> <volume>121</volume>, <fpage>198</fpage>&#x2013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.matchemphys.2010.01.020</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Heo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Nanoparticle&#x2013;hydrogel superstructures for biomedical applications</article-title>. <source>J. Control. Release</source> <volume>324</volume>, <fpage>505</fpage>&#x2013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2020.05.041</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaper</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Nataro</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Mobley</surname>
<given-names>H. L. T.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Pathogenic <italic>Escherichia coli</italic>
</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>2</volume>, <fpage>123</fpage>&#x2013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro818</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karata&#x15f;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ya&#x15f;ar-Duman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>T&#xfc;nger</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>&#xc7;illi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Aydemir</surname>
<given-names>&#x15e;.</given-names>
</name>
<name>
<surname>&#xd6;zenci</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Secondary bacterial infections and antimicrobial resistance in COVID-19: Comparative evaluation of pre-pandemic and pandemic-era, a retrospective single center study</article-title>. <source>Ann. Clin. Microbiol. Antimicrob.</source> <volume>20</volume>, <fpage>51</fpage>. <pub-id pub-id-type="doi">10.1186/s12941-021-00454-7</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasemets</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ivask</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dubourguier</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Kahru</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Toxicity of nanoparticles of ZnO, CuO and TiO2 to yeast <italic>Saccharomyces cerevisiae</italic>
</article-title>. <source>Toxicol. Vitro</source> <volume>23</volume>, <fpage>1116</fpage>&#x2013;<lpage>1122</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2009.05.015</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Akhtar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Almohazey</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Alomari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Almofty</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Extracts of clove (syzygium aromaticum) potentiate FMSP-nanoparticles induced cell death in MCF-7 cells</article-title>. <source>Int. J. Biomater.</source> <volume>2018</volume>, <fpage>8479439</fpage>. <pub-id pub-id-type="doi">10.1155/2018/8479439</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kongot</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Singhal</surname>
<given-names>N. K.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Oxidovanadium (IV) and iron (III) complexes with O2N2 donor linkage as plausible antidiabetic candidates: Synthesis, structural characterizations, glucose uptake and model biological media studies</article-title>. <source>Appl. Organomet. Chem.</source> <volume>34</volume>, <fpage>e5327</fpage>. <pub-id pub-id-type="doi">10.1002/aoc.5327</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Toxicity of ZnO nanoparticles to escherichia Coli: Mechanism and the influence of medium components</article-title>. <source>Environ. Sci. Technol.</source> <volume>45</volume>, <fpage>1977</fpage>&#x2013;<lpage>1983</lpage>. <pub-id pub-id-type="doi">10.1021/es102624t</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W. R.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X. B.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Q. S.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y. S. O.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. B.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Antibacterial activity and mechanism of silver nanoparticles on <italic>Escherichia coli</italic>
</article-title>. <source>Appl. Microbiol. Biotechnol.</source> <volume>85</volume>, <fpage>1115</fpage>&#x2013;<lpage>1122</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-009-2159-5</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>F. X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H. X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A pH-sensitive drug delivery system based on folic acid-targeted HBP-modified mesoporous silica nanoparticles for cancer therapy</article-title>. <source>Colloids Surf. A Physicochem Eng. Asp.</source> <volume>590</volume>, <fpage>124470</fpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfa.2020.124470</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>K. D.</given-names>
</name>
<name>
<surname>Nogueira</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mariotto</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Rowland</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Yabroff</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Alfano</surname>
<given-names>C. M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Cancer treatment and survivorship statistics</article-title>. <source>CA Cancer J. Clin.</source> <volume>69</volume>, <fpage>363</fpage>&#x2013;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21565</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohanty</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Arega</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ganguly</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ganguly</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>CAR T cell therapy: A new era for cancer treatment (review)</article-title>. <source>Oncol. Rep.</source> <volume>42</volume>, <fpage>2183</fpage>&#x2013;<lpage>2195</lpage>. <pub-id pub-id-type="doi">10.3892/or.2019.7335</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nadtoka</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Kutsevol</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bezugla</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Virych</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Naumenko</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Hydrogel-silver nanoparticle composites for biomedical applications</article-title>. <source>Ukrainian J. Phys.</source> <volume>65</volume>, <fpage>446</fpage>. <pub-id pub-id-type="doi">10.15407/ujpe65.5.446</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nolan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Falzon</surname>
<given-names>B. G.</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Padmanaba</surname>
<given-names>D. B.</given-names>
</name>
<name>
<surname>Maguire</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Metal nanoparticle-hydrogel nanocomposites for biomedical applications &#x2013; an atmospheric pressure plasma synthesis approach</article-title>. <source>Plasma Process. Polym.</source> <volume>15</volume>, <fpage>1800112</fpage>. <pub-id pub-id-type="doi">10.1002/ppap.201800112</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nunes</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ramalho</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Loureiro</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Polymeric nanoparticles-loaded hydrogels for biomedical applications: A systematic review on <italic>in vivo</italic> findings</article-title>. <source>Polym. (Basel)</source> <volume>14</volume>, <fpage>1010</fpage>. <pub-id pub-id-type="doi">10.3390/polym14051010</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandurangan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Enkhtaivan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. H.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Anticancer studies of synthesized ZnO nanoparticles against human cervical carcinoma cells</article-title>. <source>J. Photochem. Photobiol.</source> <volume>158</volume>, <fpage>206&#x2013;211</fpage>. <pub-id pub-id-type="doi">10.1016/j.jphotobiol.2016.03.002</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Calderon</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Progress in research on gold nanoparticles in cancer management</article-title>. <source>Med. (United States)</source> <volume>98</volume>, <fpage>e15311</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000015311</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Philpott</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Edgeworth</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Sansonetti</surname>
<given-names>P. J.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>The pathogenesis of Shigella flexneri infection: Lessons from <italic>in vitro</italic> and <italic>in vivo</italic> studies</article-title>. <source>Philosophical Trans. R. Soc. B Biol. Sci.</source> <volume>355</volume>, <fpage>575</fpage>&#x2013;<lpage>586</lpage>. <pub-id pub-id-type="doi">10.1098/rstb.2000.0599</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rafieian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mirzadeh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mahdavi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Masoumi</surname>
<given-names>M. E.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>A review on nanocomposite hydrogels and their biomedical applications</article-title>. <source>IEEE J. Sel. Top. Quantum Electron.</source> <volume>26</volume>, <fpage>154</fpage>&#x2013;<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1515/secm-2017-0161</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raghupathi</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Koodali</surname>
<given-names>R. T.</given-names>
</name>
<name>
<surname>Manna</surname>
<given-names>A. C.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Size-dependent bacterial growth inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles</article-title>. <source>Langmuir</source> <volume>27</volume>, <fpage>4020</fpage>&#x2013;<lpage>4028</lpage>. <pub-id pub-id-type="doi">10.1021/la104825u</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramalingam</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Parandhaman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S. K.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Antibacterial effects of biosynthesized silver nanoparticles on surface ultrastructure and nanomechanical properties of gram-negative bacteria viz. <italic>Escherichia coli</italic> and <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>8</volume>, <fpage>4963</fpage>&#x2013;<lpage>4976</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.6b00161</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rather</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Lew</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Kamli</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Hakeem</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Sabir</surname>
<given-names>J. S. M.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y. H.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>The inhibition of SARS-CoV-2 and the modulation of inflammatory responses by the extract of lactobacillus sakei Probio65</article-title>. <source>Vaccines (Basel)</source> <volume>10</volume>, <fpage>2106</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines10122106</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rather</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Wani</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Kamli</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Sabir</surname>
<given-names>J. S. M.</given-names>
</name>
<name>
<surname>Hakeem</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Firoz</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Limosilactobacillus fermentum KAU0021 abrogates mono- and polymicrobial biofilms formed by Candida albicans and <italic>Staphylococcus aureus</italic>
</article-title>. <source>Pharmaceutics</source> <volume>15</volume>, <fpage>1079</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics15041079</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rather</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Wani</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Kamli</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Sabir</surname>
<given-names>J. S. M.</given-names>
</name>
<name>
<surname>Hakeem</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Firoz</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Lactiplantibacillus plantarum KAU007 extract modulates critical virulence attributes and biofilm formation in sinusitis causing Streptococcus pyogenes</article-title>. <source>Pharmaceutics</source> <volume>14</volume>, <fpage>2701</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14122702</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rehman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Asiri</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Jermy</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Ravinayagam</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Alsalem</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Anticandidal and <italic>in vitro</italic> anti-proliferative activity of sonochemically synthesized indium tin oxide nanoparticles</article-title>. <source>Sci. Rep.</source> <volume>10</volume>, <fpage>3228</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-60295-w</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rehman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jermy</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Akhtar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Borgio</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Abdul Azeez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ravinayagam</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Isolation and characterization of a novel thermophile; Bacillus haynesii, applied for the green synthesis of ZnO nanoparticles</article-title>. <source>Artif. Cells Nanomed Biotechnol.</source> <volume>47</volume>, <fpage>2072</fpage>&#x2013;<lpage>2082</lpage>. <pub-id pub-id-type="doi">10.1080/21691401.2019.1620254</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shoji</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kokugan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>1998</year>). <article-title>Hydrogen peroxide as an antibacterial factor in zinc oxide powder slurry</article-title>. <source>J. Ferment Bioeng.</source> <volume>86</volume>, <fpage>521</fpage>&#x2013;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1016/S0922-338X(98)80165-7</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schirrmacher</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (review)</article-title>. <source>Int. J. Oncol.</source> <volume>54</volume>, <fpage>407</fpage>&#x2013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2018.4661</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rousso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bergeron</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Son</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>El-Sayes</surname>
<given-names>N. A.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Multi-modal potentiation of oncolytic virotherapy by vanadium compounds</article-title>. <source>Mol. Ther.</source> <volume>26</volume>, <fpage>56</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2017.10.014</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Senthil Raja</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bhuvanesh</surname>
<given-names>N. S. P.</given-names>
</name>
<name>
<surname>Natarajan</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Synthesis, crystal structure and pharmacological evaluation of two new Cu(II) complexes of 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (benzoyl) hydrazone: A comparative investigation</article-title>. <source>Eur. J. Med. Chem.</source> <volume>47</volume>, <fpage>73</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2011.10.024</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Halloysite nanotubes supported Ag and ZnO nanoparticles with synergistically enhanced antibacterial activity</article-title>. <source>Nanoscale Res. Lett.</source> <volume>12</volume>, <fpage>135</fpage>. <pub-id pub-id-type="doi">10.1186/s11671-017-1859-5</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Synthesis, physico-chemical characterization and antimicrobial activity of cobalt(II), nickel(II), copper(II), zinc(II) and cadmium(II) complexes with some acyldihydrazones</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source> <volume>23</volume>, <fpage>797</fpage>&#x2013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1080/14756360701733136</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sirelkhatim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mahmud</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Seeni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaus</surname>
<given-names>N. H. M.</given-names>
</name>
<name>
<surname>Ann</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Bakhori</surname>
<given-names>S. K. M.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Review on zinc oxide nanoparticles: Antibacterial activity and toxicity mechanism</article-title>. <source>Nanomicro Lett.</source> <volume>7</volume>, <fpage>219</fpage>&#x2013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1007/s40820-015-0040-x</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stojkovska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zvicer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Obradovic</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Preclinical functional characterization methods of nanocomposite hydrogels containing silver nanoparticles for biomedical applications</article-title>. <source>Appl. Microbiol. Biotechnol.</source> <volume>104</volume>, <fpage>4643</fpage>&#x2013;<lpage>4658</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-020-10521-2</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sulaiman</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Hamzah</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zakaria</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Che Othman</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Suffian</surname>
<given-names>I. F. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hydrogel-nanoparticle hybrids for biomedical applications: Principles and advantages</article-title>. <source>Nanomedicine</source> <volume>16</volume>, <fpage>81</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2020-0420</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suma</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Padmanabhan</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Telukutla</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Ravindran</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Velikkakath</surname>
<given-names>A. K. G.</given-names>
</name>
<name>
<surname>Dekiwadia</surname>
<given-names>C. D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Vanadium pentoxide nanoparticle mediated perturbations in cellular redox balance and the paradigm of autophagy to apoptosis</article-title>. <source>Free Radic. Biol. Med.</source> <volume>161</volume>, <fpage>198</fpage>&#x2013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.10.008</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Gold nanoparticle-induced cell death and potential applications in nanomedicine</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume>, <fpage>754</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19030754</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanino</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Amano</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tsubata</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Anticancer activity of ZnO nanoparticles against human small-cell lung cancer in an orthotopic mouse model</article-title>. <source>Mol. Cancer Ther.</source> <volume>19 (2)</volume>, <fpage>502&#x2013;512</fpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-0018</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijesundara</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rupasinghe</surname>
<given-names>H. P. V.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Carvacrol exhibits rapid bactericidal activity against Streptococcus pyogenes through cell membrane damage</article-title>. <source>Sci. Rep.</source> <volume>11</volume>, <fpage>1487</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-79713-0</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yadav</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sadique</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Pal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Cytotoxicity and DNA fragmentation-mediated apoptosis response of hexagonal ZnO nanorods against human prostate cancer cells</article-title>. <source>Appl. Surf. Sci. Adv.</source> <volume>9</volume>, <fpage>100237</fpage>. <pub-id pub-id-type="doi">10.1016/j.apsadv.2022.100237</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Influence of particle size on the antibacterial activity of zinc oxide</article-title>. <source>Int. J. Inorg. Mater.</source> <volume>3</volume>, <fpage>643</fpage>&#x2013;<lpage>646</lpage>. <pub-id pub-id-type="doi">10.1016/S1466-6049(01)00197-0</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mustapha</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Zinc oxide and silver nanoparticle effects on intestinal bacteria</article-title>. <source>Materials</source> <volume>14</volume>, <fpage>2489</fpage>. <pub-id pub-id-type="doi">10.3390/ma14102489</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Povey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>York</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>ZnO nanofluids-A potential antibacterial agent</article-title>. <source>Prog. Nat. Sci.</source> <volume>18</volume>, <fpage>939</fpage>&#x2013;<lpage>944</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnsc.2008.01.026</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Povey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>York</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Investigation into the antibacterial behaviour of suspensions of ZnO nanoparticles (ZnO nanofluids)</article-title>. <source>J. Nanoparticle Res.</source> <volume>9</volume>, <fpage>479</fpage>&#x2013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1007/s11051-006-9150-1</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>